Nothing Special   »   [go: up one dir, main page]

MX2021010558A - Albumina de suero humano en formulaciones. - Google Patents

Albumina de suero humano en formulaciones.

Info

Publication number
MX2021010558A
MX2021010558A MX2021010558A MX2021010558A MX2021010558A MX 2021010558 A MX2021010558 A MX 2021010558A MX 2021010558 A MX2021010558 A MX 2021010558A MX 2021010558 A MX2021010558 A MX 2021010558A MX 2021010558 A MX2021010558 A MX 2021010558A
Authority
MX
Mexico
Prior art keywords
formulations
serum albumin
human serum
drug formulations
preventing
Prior art date
Application number
MX2021010558A
Other languages
English (en)
Inventor
Michael Marlow
Dorothy Kim
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021010558A publication Critical patent/MX2021010558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan formulaciones farmacológicas y métodos para eliminar, reducir o prevenir la formación de partículas de ácidos grasos en formulaciones farmacológicas.
MX2021010558A 2019-03-05 2020-03-03 Albumina de suero humano en formulaciones. MX2021010558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813843P 2019-03-05 2019-03-05
PCT/US2020/020752 WO2020180850A1 (en) 2019-03-05 2020-03-03 Human serum albumin in formulations

Publications (1)

Publication Number Publication Date
MX2021010558A true MX2021010558A (es) 2021-10-13

Family

ID=70190088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010558A MX2021010558A (es) 2019-03-05 2020-03-03 Albumina de suero humano en formulaciones.

Country Status (13)

Country Link
US (2) US11241499B2 (es)
EP (1) EP3934620A1 (es)
JP (1) JP7561748B2 (es)
KR (1) KR20210135543A (es)
CN (1) CN113543811A (es)
AU (1) AU2020232683A1 (es)
BR (1) BR112021015790A2 (es)
CA (1) CA3130457A1 (es)
EA (1) EA202192422A1 (es)
IL (1) IL285938A (es)
MX (1) MX2021010558A (es)
SG (1) SG11202109004TA (es)
WO (1) WO2020180850A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116457020A (zh) * 2020-11-16 2023-07-18 W.L.戈尔及同仁股份有限公司 不含脂肪酸颗粒的制剂、方法和预填充注射装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095568A1 (en) 2013-12-18 2015-06-25 Kelvin Lee Reduction of lipase activity in product formulations
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CN108472379B (zh) * 2015-12-30 2022-06-21 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂

Also Published As

Publication number Publication date
CN113543811A (zh) 2021-10-22
EA202192422A1 (ru) 2021-12-09
KR20210135543A (ko) 2021-11-15
SG11202109004TA (en) 2021-09-29
WO2020180850A1 (en) 2020-09-10
EP3934620A1 (en) 2022-01-12
JP2022523962A (ja) 2022-04-27
IL285938A (en) 2021-10-31
US20200282063A1 (en) 2020-09-10
CA3130457A1 (en) 2020-09-10
AU2020232683A1 (en) 2021-09-02
US20220118097A1 (en) 2022-04-21
US11241499B2 (en) 2022-02-08
JP7561748B2 (ja) 2024-10-04
BR112021015790A2 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MX2020009896A (es) Celulas efectoras inmunitarias modificadas y usos de las mismas.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2024006041A (es) Celulas t modificadas y metodos para hacer y usar las mismas.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
PH12015502792A1 (en) Crystalline bromodomain inhibitors
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CA2883095C (en) Antibody and protein formulations
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
SG10201809947UA (en) Use of prg4 as an anti-inflammatory agent
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PH12018501072A1 (en) Modified release orally administered amino acid formulations
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
MX2019003988A (es) Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
MX2021007709A (es) Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1